Glyburide use is associated with a greater likelihood of mortality or rehospitalization after acute coronary syndrome compared to gliclazide use in adults with type 2 diabetes: A cohort study
Main finding · 1-year mortality or rehospitalization, any exposure in year before catheterizationResult — go to the resultAdjusted odds ratio 1.14 95% CI 0.93–1.41Authors' conclusion
Current and long exposure to glyburide was associated with a greater likelihood of mortality or rehospitalization following cardiac catheterization for acute coronary syndrome, when compared to similar gliclazide exposure definitions. This study adds further evidence of the need to avoid using glyburide if a sulphonylurea is required for type 2 diabetes management.
Study context
- Population
- Adults with T2D undergoing cardiac catheterization for acute coronary syndrome, Alberta, Canada, April 2008–March 2021; mean age 66 years, 31% female; 5% used glyburide and 19% gliclazide
- Participants
- 11,140 adults
- Exposure
- Glyburide vs gliclazide use
- Outcome
- Composite of:
- All-cause mortality
- Rehospitalization
- Follow-up
- 1 year
Methodological detailslinked clinical and administrative health data, multivariable logistic regression
- Linked clinical and administrative health data
- Multivariable logistic regression
Main finding
As reported in the abstract
1-year mortality or rehospitalization, any exposure in year before catheterization
Adjusted odds ratio
1.14
95% CI 0.93–1.41
P = 0.20
Glyburidevs Gliclazide
aOR 1.14 (95% CI 0.93–1.41); P = 0.20
Observational data: associations, not effects.
Further findings
| Outcome | aOR (95% CI) | P value | |
|---|---|---|---|
| Mortality or rehospitalization, current exposure · 1 yearCurrent exposure | 1.37 (1.06–1.79) | P = 0.018 | |
| Mortality or rehospitalization, long exposure · 1 yearLong exposure | 1.37 (1.03–1.83) | P = 0.030 | |
| 0.512Adjusted odds ratio (log scale) |
Original publication
Glyburide use is associated with a greater likelihood of mortality or rehospitalization after acute coronary syndrome compared to gliclazide use in adults with type 2 diabetes: A cohort study. Diabetes Obes Metab. Published 9 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →